San Francisco, CANCT07506239Now EnrollingIRB Ready

Low-grade Glioma Clinical Trial in San Francisco, CA

Access cutting-edge low-grade glioma treatment through this clinical trial at a research site in San Francisco. Study-provided care at no cost to qualified participants.

Sponsored by University of California, San Francisco

Quick Self-Assessment

See if you qualify for this San Francisco location

Preparing your pre-screening questions…

Expert Care in San Francisco

Access low-grade glioma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related low-grade glioma treatment provided free

Apply for This San Francisco Location

Check if you qualify for this low-grade glioma clinical trial in San Francisco, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to San Francisco

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit San Francisco site if eligible
  4. 4Begin participation

About This Low-grade Glioma Study in San Francisco

This study aims to evaluate the efficacy of Laser Interstitial Thermal Therapy (LITT) in treating recurrent or progressive, low-grade gliomas (LGG) in pediatric, adolescent and young adult patients.

Sponsor: University of California, San Francisco

Who Can Participate

Inclusion Criteria

Participants must have recurrent or progressive pediatric LGG who have received at least one prior treatment. Prior treatment may include surgery alone and/or systemic therapy.
Participants must have histologically confirmed LGG that is recurrent or progressive after prior treatment and determined to be a candidate for LITT by central review. All patients will undergo central review prior to LITT. Any number of previous recurrences are permissible provided the participant meets other enrollment criteria.
Tumor size: up to 5 cm in largest dimension not including any cystic component. Larger tumors will need to be discussed with the study team. Additional adjunctive interventions such as cyst aspiration prior to or concurrent with a LITT procedure is allowed at the treating surgeon's discretion. Tumor location: Tumors must be located in areas of the brain or central nervous system that are accessible and considered safe for LITT, as determined by central review.
Suprasellar gliomas not arising from the optic pathway are eligible.
Multifocal or metastatic LGGs are eligible, provided that the growing lesions are suitable for LITT.
Exophytic brainstem lesions, which are more accessible and present a lower risk, may be eligible for LITT.
A patient with stable leptomeningeal disease and a separate growing lesion suitable for LITT is eligible for the study.
Prior Therapy: Participants may have had LITT for other medical indications, provided that the lesion being considered for this study has not previously undergone LITT, except for patients who have received LITT for an intracranial lesion that has shown progression post-LITT beyond 15 months would be eligible.
Participants must have fully recovered from the acute toxic effects of all prior chemotherapy or targeted therapy prior to entering this study and would be eligible for surgical intervention per institutional guidelines.
Bevacizumab: participants must have received last dose \> 21 days prior to study registration.
Participants must have had chemotherapy \> 3 weeks (6 weeks for nitrosoureas or mitomycin C) prior to registration.
Participants must be at least 7 days since the completion of therapy with a biologic or small molecule agent. For any agent with known adverse events that can occur beyond 7 days after administration, the period prior to enrollment must be beyond the time during which adverse events are known to occur. Such patients should also be discussed with study chairs.
Radiation: Participants must have:
Had their last fraction of local irradiation or focal radiosurgery to primary tumor ≥12 weeks prior to registration.
Had their last fraction of craniospinal irradiation or total body irradiation ≥ 12 weeks prior to registration
Age \>= 2 years to \<= 25 years of age
Performance Score: Karnofsky ≥ 50 for participants \> 16 years of age and Lansky ≥ 50 for participants ≤ 16 years of age. Participants who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.
Corticosteroids: Participants who are receiving dexamethasone must be on a stable or decreasing dose for at least 1 week prior to registration.
Patients must be surgically eligible per institutional standards.
Patients must co-enroll to Pediatric Neuro-oncology Consortium (PNOC) COMP if PNOC COMP is open to accrual at the enrolling institution.
A legal parent/guardian or patient must be able to understand, and willing to sign, a written informed consent and assent document, as appropriate.

Exclusion Criteria

Any contraindication to the use of LITT, such as but not limited to:
Optic pathway gliomas
Spinal tumors
Brainstem Lesions: Infiltrative brainstem lesions are excluded. However, exophytic brainstem lesions, which are more accessible and present a lower risk, may be eligible for LITT.
Any lesion/location determined by central review to be contraindicated for LITT.
The presence of uncontrolled leptomeningeal disease or extracranial disease including:
Evidence of untreated obstructive hydrocephalus or mass effect causing \>10 millimeter (mm) midline shift
Presence of symptomatic intratumoral hemorrhage (Grade 3 \& 4). Intratumoral hemorrhage grade 2 needs to be discussed with study team.
Participants who are receiving any other investigational agents.
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection. Important note: The eligibility criteria listed above are interpreted literally and cannot be waived.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in San Francisco?

Yes, this clinical trial (NCT07506239) has an active research site in San Francisco, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Low-grade Glioma Treatment Options in San Francisco, CA

If you're searching for low-grade glioma treatment options in San Francisco, CA, this clinical trial (NCT07506239) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our San Francisco research site is actively enrolling participants for this clinical trial. You'll receive care from experienced low-grade glioma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all low-grade glioma clinical trials near you to find additional studies recruiting in your area.

More Brain Cancer Trials in San Francisco, CA

See all brain cancer clinical trials recruiting in San Francisco — not just this study.

Browse Brain Cancer Trials in San Francisco →

Browse More Trials by Condition

Brain Cancer TrialsAlzheimers Disease TrialsRheumatoid Arthritis TrialsAtopic Dermatitis TrialsAll Conditions →

Ready to Join in San Francisco?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · San Francisco, CA